Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41585-020-00382-9 http://scihub22266oqcxt.onion/10.1038/s41585-020-00382-9 33051619!7551522!33051619     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Rev+Urol 2020 ; 17 (12): 659-678 Nephropedia Template TP {{tp|p=33051619|t=2020. Sarcomatoid renal cell carcinoma: biology, natural history and management |pdf=|usr=}}{{33051619}} gab.com Text Sarcomatoid renal cell carcinoma: biology, natural history and management JO: Nat Rev Urol http://www.kidney.de/pget.php?&tw=1&pmid=33051619 #FOAvip Sarcomatoid dedifferentiation is an uncommon feature that can occur in most histological subtypes of renal cell carcinomas (RCCs) and carries a decidedly poor prognosis. Historically, conventional treatments for sarcomatoid RCCs (sRCCs) have shown little efficacy, and median survival is commonly 6-13 months. Despite being first described in 1968, the mechanisms driving sarcomatoid dedifferentiation remain poorly understood, and information and treatment options available to physicians and patients are limited. When diagnosed at an early stage, surgical intervention remains the treatment of choice. However, preoperative identification through routine imaging or biopsy is unreliable and most patients present with advanced disease and systemic symptoms. For these patients, the role of cytoreductive nephrectomy is disputed. The expansion of immunotherapies approved for RCCs has generated a search for biomarkers that might be indicative of treatment response in sRCCs, although a proven effective systemic agent remains elusive. PDL1 expression is increased in sarcomatoid dedifferentiated renal tumours, which suggests that patients with sRCCs could benefit from PD1 and/or PDL1 immune checkpoint blockade therapy. Treatment outcomes for sarcomatoid tumours have remained relatively consistent compared with other RCCs, but further investigation of the tumour-immune cell microenvironment might yield insights into further therapeutic possibilities. Twit Text FOAVip Sarcomatoid renal cell carcinoma: biology, natural history and management ????Nat Rev Urol http://www.kidney.de/pget.php?&tw=1&pmid=33051619 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33051619 #FOAvip English Wikipedia <ref>{{Cite pmid|33051619}}</ref> Sarcomatoid renal cell carcinoma: biology, natural history and management #MMPMID33051619 Blum KA; Gupta S; Tickoo SK; Chan TA; Russo P; Motzer RJ; Karam JA; Hakimi AA Nat Rev Urol 2020[Dec]; 17 (12): 659-678 PMID33051619show ga Sarcomatoid dedifferentiation is an uncommon feature that can occur in most histological subtypes of renal cell carcinomas (RCCs) and carries a decidedly poor prognosis. Historically, conventional treatments for sarcomatoid RCCs (sRCCs) have shown little efficacy, and median survival is commonly 6-13 months. Despite being first described in 1968, the mechanisms driving sarcomatoid dedifferentiation remain poorly understood, and information and treatment options available to physicians and patients are limited. When diagnosed at an early stage, surgical intervention remains the treatment of choice. However, preoperative identification through routine imaging or biopsy is unreliable and most patients present with advanced disease and systemic symptoms. For these patients, the role of cytoreductive nephrectomy is disputed. The expansion of immunotherapies approved for RCCs has generated a search for biomarkers that might be indicative of treatment response in sRCCs, although a proven effective systemic agent remains elusive. PDL1 expression is increased in sarcomatoid dedifferentiated renal tumours, which suggests that patients with sRCCs could benefit from PD1 and/or PDL1 immune checkpoint blockade therapy. Treatment outcomes for sarcomatoid tumours have remained relatively consistent compared with other RCCs, but further investigation of the tumour-immune cell microenvironment might yield insights into further therapeutic possibilities. |*Epithelial-Mesenchymal Transition[MESH] |*Nephrectomy[MESH] |B7-H1 Antigen/metabolism[MESH] |Carcinoma, Renal Cell/metabolism/*pathology/therapy[MESH] |Disease Management[MESH] |Humans[MESH] |Immune Checkpoint Inhibitors/*therapeutic use[MESH] |Kidney Neoplasms/metabolism/*pathology/therapy[MESH] |Lymphocytes, Tumor-Infiltrating[MESH] |Prognosis[MESH] |Programmed Cell Death 1 Receptor/metabolism[MESH]Sarcomatoid renal cell carcinoma: biology, natural history and managem(epmc).pdf DeepDyve Pubget Overpricing